# Novus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novus-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Irvine, US
- Website: www.novustherapeutics.com
- Total disclosed funding: $57M
- Latest round: Series E (May 15, 2013)
- Investors on record: 3

## About

Novus Therapeutics Inc. focuses on developing innovative therapies aimed at improving organ transplant outcomes, particularly through the development of immunomodulatory treatments that enhance patient quality of life post-transplant.Novus Therapeutics Inc. was formed in May 2017 through the merger of Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., originally founded in 2004 and headquartered in Irvine, US. The company has completed a total of 9 deals, with the most recent funding round being a Private Placement/Follow on that raised USD 10.67 mn on April 30, 2019. The current CEO is David-Alexandre Gros.Novus Therapeutics specializes in developing therapies focused on organ transplant outcomes, with a leading product, tegoprubart, an anti-CD40L antibody that regulates immune responses to mitigate organ rejection. The company is conducting pivotal clinical trials, including the BESTOW trial for kidney transplant patients, and is exploring applications of tegoprubart in liver transplantation and xenotransplantation, primarily in North America and Europe.Novus Therapeutics generates revenue from its clinical development programs around tegoprubart, engaging in partnerships with clinical trial sites and healthcare providers. Revenue streams are established through clinical trial agreements and licensing deals aimed at advancing their therapies, with potential commercialization leading to milestone payments and royalties from therapy sales.Looking ahead, Novus Therapeutics plans to expand its product offerings and geographical footprint. The company is actively working on new therapies and exploring markets, specifically in North America and Europe. The recent funding round of USD 10.67 mn will be strategically utilized to support these initiatives, allowing Novus to progress its clinical trials and potentially enable future commercialization of its therapies.

## Funding rounds

- Series E, May 15, 2013, $20M — Novartis Venture Fund, Apple Tree Partners
- Series D, Dec 13, 2011, $13M — QIC
- Series D, Sep 20, 2011, $1.9M — Novartis Venture Fund, Apple Tree Partners
- Series D, May 8, 2009, $22M — Novartis Venture Fund, Apple Tree Partners

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series D, Series E
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series D, Series E
- QIC (https://capitalatlas.ai/funds/qic) — Series D